Clinical Trials Logo

Filter by:
NCT ID: NCT06009185 Completed - Clinical trials for Pulmonary Arterial Hypertension

Safety and Efficacy of BIA 5-1058 in PAH

Start date: June 26, 2019
Phase: Phase 2
Study type: Interventional

This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.

NCT ID: NCT06008080 Recruiting - Aortic Stenosis Clinical Trials

Post-Market Clinical Follow Up Study With Navitor Valve

VISTA
Start date: September 29, 2023
Phase:
Study type: Observational

Evaluation of the safety and performance of the Navitor TAVI System in a Global Study

NCT ID: NCT06007170 Recruiting - Clinical trials for Bilateral Vocal Cord Paralysis

Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients Without Glottal Enlargement

Start date: July 27, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP). The main questions it aims to answer are: - Is the use of the device safe? - Does the device improve the participants ability to take a breath? Participants will be implanted with the SPIRION Laryngeal Pacemaker and the development of their symptoms will be observed for the following 2 years.

NCT ID: NCT06007144 Recruiting - Clinical trials for Bilateral Vocal Cord Paralysis

Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients With Single-sided Glottal Enlargement

Start date: August 18, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical investigation is to learn about the use of a novel medical device, the SPIRION Laryngeal Pacemaker, in patients suffering from bilateral vocal fold paralysis (BVFP) and who have had at least one related surgery on one of their vocal folds. The main questions it aims to answer are: - Is the use of the device safe? - Does the device improve the participants ability to take a breath? Participants will be implanted with the SPIRION Laryngeal Pacemaker and the development of their symptoms will be observed for the following 2 years.

NCT ID: NCT06006754 Recruiting - Clinical trials for Acute Myocardial Infarction

Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock

Start date: August 30, 2023
Phase:
Study type: Observational

Cardiogenic shock is associated with a high mortality. The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects. The significance of the enteral micobiome on cardiovascular mortality of patients with cardiogenic shock is still not known. This study aims to provide a deeper understanding of the role of the enteral microbiome and microbiome dependent metabolites in mortality and disease progression of patients with cardiogenic shock.

NCT ID: NCT06006598 Completed - Healthy Clinical Trials

A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy Men

Start date: August 28, 2023
Phase: Phase 1
Study type: Interventional

The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 1584862 in healthy male subjects following administration of multiple rising doses.

NCT ID: NCT06005350 Active, not recruiting - NAD Clinical Trials

Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)

NICE
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The investigation is a clinical study in which the impact of taking the dietary supplement nicotinamide riboside (NR) on the concentration of extracellular nicotinamide adenine dinucleotide (eNAD+) in human plasma over time will be determined. The study will be conducted in a randomized, double-blinded, and placebo-controlled manner.

NCT ID: NCT06005246 Recruiting - Clinical trials for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (ICD-10 G93.3)

Munich ME/CFS Cohort Study

MUC-CFS
Start date: January 22, 2019
Phase:
Study type: Observational

The Munich cohort study MUC-CFS aims at the characterization and long-term follow-up of myalgic encephalitis/chronic fatigue syndrome (ME/CFS) in young people aged up to 25 years, as well as at the identification of pathomechanisms, biomarkers, and targets for future treatment approaches.

NCT ID: NCT06005233 Not yet recruiting - Atrial Fibrillation Clinical Trials

Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke

WATCH AFib
Start date: July 2024
Phase: N/A
Study type: Interventional

Scientific Background: In secondary prevention of ischemic stroke, detection of atrial fibrillation (AFib) and subsequent anticoagulation therapy reduce the risk of recurrent stroke by approximately 60%. Prolonged electrocardiogram (ECG) monitoring up to 6 months significantly increases detection of AFib in cryptogenic stroke. Wearables like smartwatches have recently been shown to adequately detect AFib in the general population. Thus, prolonged ECG monitoring after cryptogenic ischemic stroke or transient ischemic attack (TIA) using a smartwatch could lead to a reduction of recurrent stroke by prompting adequate anticoagulation therapy and may constitute a cost-effective, non-invasive, and broadly-available alternative to the current standard of care. Hypothesis: The investigators hypothesize that AFib detection via smartwatch in patients with cryptogenic TIA or ischemic stroke is accurate compared to an implantable event recorder. Methods: The investigators introduce a prospective, intraindividual-controlled, multicentre clinical study in patients with cryptogenic ischemic stroke or TIA. In addition to an implanted event recorder as indicated by clinical standard, included patients receive a smartwatch for detection of AFib. ECG-data from smartwatches will be continuously monitored by two independent cardiologists. As soon as AFib is confirmed, a doctoral appointment is set to evaluate start of anticoagulation. The follow-up period will be six months. The study consists of four study visits: a baseline visit, two phone visits at one and three months, and an end of trial visit at six months. Primary Objective: To compare smartwatch and event recorder based analysis for sensitivity and specificity of AFib detection per patient after six months

NCT ID: NCT06004531 Recruiting - Anxiety Clinical Trials

Planetary Health and Loneliness

PAL
Start date: August 28, 2023
Phase: N/A
Study type: Interventional

The aim of this online study is the evaluation of planetary health behaviors in relation to levels of eco-anxiety, general well-being, and levels of loneliness. As climate change progresses at a dangerous rate, it is important to establish and maintain lifestyles that are productive, fulfilling, environmentally conscious, and low in anxiety. Through a better understanding of the interconnected nature of planetary health behaviors with other aspects of healthy living and perception of social isolation, this study will add to current state of science to help inform the creation of interventions promoting sustainable, healthy, happy living among the general public and specific subgroups.